Helsinn Enters into an Exclusive Distribution and License Agreement with Blanver and Varifarma for Pracinostat in South America

 Helsinn Enters into an Exclusive Distribution and License Agreement with Blanver and Varifarma for Pracinostat in South America

Helsinn Enters into an Exclusive Distribution and License Agreement with Blanver and Varifarma for Pracinostat in South America

Shots:

  • Blanver to register, promote, distribute & commercialize Pracinostat in Brazil while Varifarma to get rights in Argentina, Bolivia, Chile, Colombia, Ecuador, Paraguay, Peru, and Uruguay. Helsinn to retain rights all international developments including clinical activities & supply of Pracinostat
  • In 2016, MEI Pharma granted global rights of Pracinostat to Helsinn and a right to sub-license it to the third parties. Helsinn granted exclusive licensing rights of Pracinostat for all territories to Menarini excluding the US, Canada, Japan and South America
  • Pracinostat is an oral pan histone deacetylase inhibitor, currently being evaluated in P-III study in combination with Azacitidine for patients newly diagnosed with AML who are unfit for intensive induction CT and has received FDA’s BT designation for the same indication

Click here to­ read full press release/ article | Ref: Helsinn | Image: Twitter

Tuba Khan

Tuba Khan is Senior Editor at PharmaShots. She is curious, creative, and passionate about recent updates and innovation in the Life sciences industry. She covers Biopharma, MedTech, and Digital health segments. Tuba also has an experience of digital and social media marketing and runs the campaigns independently. She can be contacted on tuba@pharmashots.com

Related post